GlaxoSmithKline Pharmaceuticals Future Growth
Future criteria checks 2/6
GlaxoSmithKline Pharmaceuticals is forecast to grow earnings and revenue by 16.8% and 8.8% per annum respectively. EPS is expected to grow by 17% per annum. Return on equity is forecast to be 40.7% in 3 years.
Key information
16.8%
Earnings growth rate
17.0%
EPS growth rate
| Pharmaceuticals earnings growth | 17.7% |
| Revenue growth rate | 8.8% |
| Future return on equity | 40.7% |
| Analyst coverage | Low |
| Last updated | 31 Oct 2024 |
Recent future growth updates
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 01
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Recent updates
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 01We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 44,125 | 10,672 | 11,105 | 11,733 | 3 |
| 3/31/2026 | 40,786 | 9,811 | 10,123 | 10,753 | 4 |
| 3/31/2025 | 37,139 | 8,567 | 7,294 | 8,515 | 4 |
| 9/30/2024 | 35,605 | 6,750 | 9,401 | 9,713 | N/A |
| 6/30/2024 | 35,067 | 6,400 | N/A | N/A | N/A |
| 3/31/2024 | 34,537 | 5,900 | 5,508 | 5,820 | N/A |
| 12/31/2023 | 33,114 | 5,289 | N/A | N/A | N/A |
| 9/30/2023 | 33,084 | 6,478 | 6,449 | 6,890 | N/A |
| 6/30/2023 | 32,683 | 6,237 | N/A | N/A | N/A |
| 3/31/2023 | 32,517 | 6,076 | 4,402 | 4,842 | N/A |
| 12/31/2022 | 32,739 | 4,195 | N/A | N/A | N/A |
| 9/30/2022 | 32,875 | 3,940 | 3,786 | 4,133 | N/A |
| 6/30/2022 | 33,048 | 3,897 | N/A | N/A | N/A |
| 3/31/2022 | 32,780 | 3,808 | 7,761 | 8,107 | N/A |
| 12/31/2021 | 34,861 | 5,100 | N/A | N/A | N/A |
| 9/30/2021 | 34,708 | 4,962 | 7,912 | 8,354 | N/A |
| 6/30/2021 | 33,403 | 3,684 | N/A | N/A | N/A |
| 3/31/2021 | 29,256 | 2,873 | 5,337 | 5,779 | N/A |
| 12/31/2020 | 31,609 | 4,819 | N/A | N/A | N/A |
| 9/30/2020 | 30,823 | -3,358 | 3,860 | 5,419 | N/A |
| 6/30/2020 | 30,850 | 905 | N/A | N/A | N/A |
| 3/31/2020 | 32,244 | 932 | 3,346 | 4,905 | N/A |
| 12/31/2019 | 31,994 | 1,019 | N/A | N/A | N/A |
| 9/30/2019 | 32,461 | 8,768 | 2,845 | 5,758 | N/A |
| 6/30/2019 | 31,804 | 4,749 | N/A | N/A | N/A |
| 3/31/2019 | 31,281 | 4,454 | 1,182 | 4,095 | N/A |
| 3/31/2018 | 28,715 | 3,507 | N/A | 4,728 | N/A |
| 3/31/2017 | 29,085 | 3,368 | N/A | 2,344 | N/A |
| 3/31/2016 | 28,379 | 3,761 | N/A | 1,389 | N/A |
| 3/31/2015 | 26,384 | 3,811 | N/A | 2,701 | N/A |
| 12/31/2013 | 25,597 | 4,817 | N/A | 2,813 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GLAXO's forecast earnings growth (16.8% per year) is above the savings rate (6.7%).
Earnings vs Market: GLAXO's earnings (16.8% per year) are forecast to grow slower than the Indian market (18% per year).
High Growth Earnings: GLAXO's earnings are forecast to grow, but not significantly.
Revenue vs Market: GLAXO's revenue (8.8% per year) is forecast to grow slower than the Indian market (10.5% per year).
High Growth Revenue: GLAXO's revenue (8.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GLAXO's Return on Equity is forecast to be very high in 3 years time (40.7%).